Thomas Gaj

Dr. Thomas Gaj


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Molecular Therapy
Verified
Journal Article
Open access
CLColin K.W. Lim
Colin K.W. Lim
MGMichael Gapinske
Michael Gapinske
ABAlexandra K. Brooks
Alexandra K. Brooks
WWWendy S. Woods
Wendy S. Woods
JPJackson E. Powell
Jackson E. Powell
TGThomas Gaj
Thomas Gaj
Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal disorder that can be caused by mutations in the superoxide dismutase 1 (SOD1) gene. Although ALS is currently incurable, CRISPR base editors hold the potential to treat the disease through their ability to create nonsense mutations that can permanently disable the expression of the mutant SOD1 gene. However, the restrictive carrying capacity of adeno-associated virus (AAV) vectors has limited their therapeutic application. In this study, we establish an intein-mediated trans-splicing system that enables in vivo delivery of cytidine base editors (CBEs) consisting of the widely used Cas9 protein from Streptococcus pyogenes. We show that intrathecal injection of dual AAV particles encoding a split-intein CBE engineered to trans-splice and introduce a nonsense-coding substitution into a mutant SOD1 gene prolonged survival and markedly slowed the progression of disease in the G93A-SOD1 mouse model of ALS. Adult animals treated by this split-intein CRISPR base editor had a reduced rate of muscle atrophy, decreased muscle denervation, improved neuromuscular function, and up to 40% fewer SOD1 immunoreactive inclusions at end-stage mice compared to control mice. This work expands the capabilities of single-base editors and demonstrates their potential for gene therapy.

1 December 2017 in Science Advances
Verified
Journal Article
Open access
PDF file
TGThomas Gaj
Thomas Gaj
DODavid S. Ojala
David S. Ojala
FEFreja K. Ekman
Freja K. Ekman
LBLeah C. Byrne
Leah C. Byrne
PLPrajit Limsirichai
Prajit Limsirichai
DSDavid Schaffer
David Schaffer
CRISPR-Cas9–mediated genome editing can be used to treat ALS in an animal model of the disease.

1 September 2019 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
FEFreja K. Ekman
Freja K. Ekman
DODavid S. Ojala
David S. Ojala
MAMaroof M. Adil
Maroof M. Adil
PLPaola A. Lopez
Paola A. Lopez
DSDavid Schaffer
David Schaffer
TGThomas Gaj
Thomas Gaj
Huntington's disease (HD) is a currently incurable and, ultimately, fatal neurodegenerative disorder caused by a CAG trinucleotide repeat expansion within exon 1 of the huntingtin (HTT) gene, which results in the production of a mutant protein that forms inclusions and selectively destroys neurons in the striatum and other adjacent structures. The RNA-guided Cas9 endonuclease from CRISPR-Cas9 systems is a versatile technology for inducing DNA double-strand breaks that can stimulate the introduction of frameshift-inducing mutations and permanently disable mutant gene function. Here, we show that the Cas9 nuclease from Staphylococcus aureus, a small Cas9 ortholog that can be packaged alongside a single guide RNA into a single adeno-associated virus (AAV) vector, can be used to disrupt the expression of the mutant HTT gene in the R6/2 mouse model of HD following its in vivo delivery to the striatum. Specifically, we found that CRISPR-Cas9-mediated disruption of the mutant HTT gene resulted in a ∼50% decrease in neuronal inclusions and significantly improved lifespan and certain motor deficits. These results thus illustrate the potential for CRISPR-Cas9 technology to treat HD and other autosomal dominant neurodegenerative disorders caused by a trinucleotide repeat expansion via in vivo genome editing.

21 January 2022 in Science Advances
Verified
Journal Article
Open access
JPJackson E. Powell
Jackson E. Powell
CLColin K. W. Lim
Colin K. W. Lim
RKRamya Krishnan
Ramya Krishnan
TMTristan X. McCallister
Tristan X. McCallister
CSChristian Saporito-Magriña
Christian Saporito-Magriña
TGThomas Gaj
Thomas Gaj
Cas13 nucleases are a class of programmable RNA-targeting CRISPR effector proteins that are capable of silencing target gene expression in mammalian cells. Here, we demonstrate that RfxCas13d, a Cas13 ortholog with favorable characteristics to other family members, can be delivered to the mouse spinal cord and brain to silence neurodegeneration-associated genes. Intrathecally delivering an adeno-associated virus vector encoding an RfxCas13d variant programmed to target superoxide dismutase 1 (SOD1), a protein whose mutation can cause amyotrophic lateral sclerosis, reduced SOD1 mRNA and protein in the spinal cord by >50% and improved outcomes in a mouse model of the disorder. We further show that intrastriatally delivering an RfxCas13d variant programmed to target huntingtin (HTT), a protein whose mutation is causative for Huntington’s disease, led to a ~50% reduction in HTT protein in the mouse brain. Our results establish RfxCas13d as a versatile platform for knocking down gene expression in the nervous system.

1 July 2021 in Trends in Biotechnology
Verified
Journal Article
Closed access
MCM. Alejandra Zeballos C.
M. Alejandra Zeballos C.
TGThomas Gaj
Thomas Gaj

14 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCM. Alejandra Zeballos C.
M. Alejandra Zeballos C.
HMHayden J. Moore
Hayden J. Moore
TSTyler J. Smith
Tyler J. Smith
JPJackson E. Powell
Jackson E. Powell
NANajah S. Ahsan
Najah S. Ahsan
TGThomas Gaj
Thomas Gaj
The TDP-43 proteinopathies, which include amyotrophic lateral sclerosis and frontotemporal dementia, are a devastating group of neurodegenerative disorders that are characterized by the mislocalization and aggregation of TDP-43. Here we demonstrate that RNA-targeting CRISPR effector proteins, a programmable class of gene silencing agents that includes the Cas13 family of enzymes and Cas7–11, can be used to mitigate TDP-43 pathology when programmed to target ataxin-2, a modifier of TDP-43-associated toxicity. In addition to inhibiting the aggregation and transit of TDP-43 to stress granules, we find that the in vivo delivery of an ataxin-2-targeting Cas13 system to a mouse model of TDP-43 proteinopathy improved functional deficits, extended survival, and reduced the severity of neuropathological hallmarks. Further, we benchmark RNA-targeting CRISPR platforms against ataxin-2 and find that high-fidelity forms of Cas13 possess improved transcriptome-wide specificity compared to Cas7–11 and a first-generation effector. Our results demonstrate the potential of CRISPR technology for TDP-43 proteinopathies.